Supplementary Table S15 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade

Supplementary Table S15 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade

<p>Statistical test for proportions of CD8+ T cell clusters in the tumor immune microenvironment stratified by histological response and timepoint</p>

Saved in:

書目詳細資料
主要作者:	Xianli Jiang (19800846) (author)
其他作者:	Nils-Petter Rudqvist (20366859) (author), Bo Jiang (15062179) (author), Shengbin Ye (21980122) (author), Shan He (21980125) (author), Qingnan Liang (21980128) (author), Jinzhuang Dou (21980131) (author), Michelle D. Williams (20574581) (author), Joe Dan Dunn (15470569) (author), Jason M. Johnson (15026883) (author), Keiko Akagi (15062170) (author), Weihong Xiao (15062188) (author), Shaoheng Liang (21980134) (author), Satvik Elayavalli (21980137) (author), Baohua Sun (21225922) (author), Edwin R. Parra (14939354) (author), Renata Ferrarotto (15026874) (author), Adam S. Garden (20574569) (author), Clifton David Fuller (21980140) (author), Jay Reddy (21980143) (author), Neil D. Gross (15026904) (author), Miriam N. Lango (21980146) (author), Cheuk Hong Leung (20374620) (author), Suyu Liu (15106072) (author), Diane D. Liu (15105910) (author), Meng Li (21980149) (author), J. Jack Lee (15027051) (author), Michael A. Curran (18247236) (author), Jack Phan (21980152) (author), Ken Chen (10185975) (author), Maura L. Gillison (15062197) (author)
出版:	2025
主題:	Cancer Cancer Biology Immuno-oncology Methods and Technology Head, Neck & Oral Cancers Immunology Immune responses to cancer Regulatory T cells Immunotherapy Checkpoint blockade Combination immunotherapy Single Cell Technologies Viral Oncogenesis Human tumor viruses
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!

相似書籍

Supplementary Table S10 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
由: Xianli Jiang (19800846)
出版: (2025)

Supplementary Table S11 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
由: Xianli Jiang (19800846)
出版: (2025)

Supplementary Table S12 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
由: Xianli Jiang (19800846)
出版: (2025)

Supplementary Table S13 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
由: Xianli Jiang (19800846)
出版: (2025)

Supplementary Table S14 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
由: Xianli Jiang (19800846)
出版: (2025)

Supplementary Table S16 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
由: Xianli Jiang (19800846)
出版: (2025)

Supplementary Table S17 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
由: Xianli Jiang (19800846)
出版: (2025)

Supplementary Table S18 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
由: Xianli Jiang (19800846)
出版: (2025)

Supplementary Table S19 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
由: Xianli Jiang (19800846)
出版: (2025)

Supplementary Table S20 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
由: Xianli Jiang (19800846)
出版: (2025)

Supplementary Table S7 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
由: Xianli Jiang (19800846)
出版: (2025)

Supplementary Table S8 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
由: Xianli Jiang (19800846)
出版: (2025)

Supplementary Table S9 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
由: Xianli Jiang (19800846)
出版: (2025)

Supplementary Table S2 from Genomic Profiling of Radiation-Induced Sarcomas Reveals the Immunologic Characteristics and Its Response to Immune Checkpoint Blockade
由: Dong-Chun Hong (16374308)
出版: (2025)

Supplementary Figure S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
由: Alessio Cortellini (11023993)
出版: (2025)

Supplementary Figure S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
由: Alessio Cortellini (11023993)
出版: (2025)

Supplementary Figure S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
由: Alessio Cortellini (11023993)
出版: (2025)

Supplementary Figure S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
由: Alessio Cortellini (11023993)
出版: (2025)

Supplementary Figure S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
由: Alessio Cortellini (11023993)
出版: (2025)

Supplementary Figure S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
由: Alessio Cortellini (11023993)
出版: (2025)

Supplementary Figure S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
由: Alessio Cortellini (11023993)
出版: (2025)

Supplementary Figure S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
由: Alessio Cortellini (11023993)
出版: (2025)

Supplementary Table S1 from SARC028 Samples Reveal an Interplay between TGF-β, IFN Signaling, and Low HLA Class I Expression as Contributors to Ewing Sarcoma Checkpoint Blockade Resistance
由: Jessica D. Daley (22128489)
出版: (2025)

Supplementary Table S2 from SARC028 Samples Reveal an Interplay between TGF-β, IFN Signaling, and Low HLA Class I Expression as Contributors to Ewing Sarcoma Checkpoint Blockade Resistance
由: Jessica D. Daley (22128489)
出版: (2025)

Supplementary Table 1 from CD161 Characterizes an Inflamed Subset of Cytotoxic T Lymphocytes Associated with Prolonged Survival in Human Papillomavirus–Driven Oropharyngeal Cancer
由: Ye Wei (15136128)
出版: (2025)

Table S1 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
由: Michael Wichroski (22165552)
出版: (2025)

Table S2 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
由: Michael Wichroski (22165552)
出版: (2025)

Table S3 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
由: Michael Wichroski (22165552)
出版: (2025)

Table S4 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
由: Michael Wichroski (22165552)
出版: (2025)

Table S5 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
由: Michael Wichroski (22165552)
出版: (2025)

Supplementary Figure S1 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
由: Ka-Won Noh (22618441)
出版: (2025)

Supplementary Figure S2 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
由: Ka-Won Noh (22618441)
出版: (2025)

Supplementary Figure S3 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
由: Ka-Won Noh (22618441)
出版: (2025)

Supplementary Figure S4 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
由: Ka-Won Noh (22618441)
出版: (2025)

Supplementary Figure S5 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
由: Ka-Won Noh (22618441)
出版: (2025)

Supplementary Table S1 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
由: Ka-Won Noh (22618441)
出版: (2025)

Supplementary Table S11 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
由: Ka-Won Noh (22618441)
出版: (2025)

Supplementary Table S3 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
由: Ka-Won Noh (22618441)
出版: (2025)

Supplementary Table S4 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
由: Ka-Won Noh (22618441)
出版: (2025)

Supplementary Tables S6-S9 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
由: Ka-Won Noh (22618441)
出版: (2025)